Search

Your search keyword '"Tsao, May"' showing total 641 results
Start Over Author "Tsao, May"
641 results on '"Tsao, May"'

3. Extremities

Author

Tsao, May N., Barnes, Elizabeth A., Joseph, Kurian Jones, editor, Veness, Michael J., editor, Barnes, Elizabeth, editor, and Rembielak, Agata, editor

Published
2023
Full Text
View/download PDF

4. Ear

Author

Barnes, Elizabeth A., Tsao, May N., Joseph, Kurian Jones, editor, Veness, Michael J., editor, Barnes, Elizabeth, editor, and Rembielak, Agata, editor

Published
2023
Full Text
View/download PDF

10. Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline.

Author

Tsao, May N, Sahgal, Arjun, Xu, Wei, De Salles, Antonio, Hayashi, Motohiro, Levivier, Marc, Ma, Lijun, Martinez, Roberto, Régis, Jean, Ryu, Sam, Slotman, Ben J, and Paddick, Ian

Subjects
acoustic, neuroma, schwannoma, systematic review, vestibular, Cancer, Neurosciences
Abstract

ObjectivesThe aim of this systematic review was to develop International Stereotactic Radiosurgery Society (ISRS) consensus guideline statements for vestibular schwannoma.MethodsA systematic review of the literature was performed up to April 2015.ResultsA total of 55 full-text articles were included in the analysis. All studies were retrospective, except for 2 prospective quality of life studies. Five-year tumour control rates with Gamma Knife radiosurgery (RS), single fraction linac RS, or fractionated (either hypofractionated or conventional fractionation) stereotactic radiation therapy (FSRT) were similar at 81-100%. The single fraction RS series (linac or Gamma Knife) with tumour marginal doses between 12 and 14 Gy revealed 5-year tumour control rates of 90-99%, hearing preservation rates of 41-79%, facial nerve preservation rates of 95-100% and trigeminal preservation rates of 79-99%.There were 6 non-randomized studies comparing single fraction RS versus FSRT. There was no statistically significant difference in tumour control; HR=1.66 (95% CI 0.81, 3.42), p =0.17, facial nerve function; HR = 0.67 (95% CI 0.30, 1.49), p =0.33, trigeminal nerve function; HR = 0.80 (95% CI 0.41, 1.56), p =0.51, and hearing preservation; HR = 1.10 (95% CI 0.72, 1.68), p =0.65 comparing single fraction RS with FSRT.Nine quality of life reports yielded conflicting results as to which modality (surgery, observation, or radiation) was associated with better quality of life outcomes.ConclusionsThere are no randomized trials to help guide management of patients with vestibular schwannoma. Within the limitations of the retrospective series, a number of consensus statements were made.

Published
2017

11. Timing of Radiation Pneumonitis in Patients with Stage 3 Non-Small-Cell Lung Cancer Receiving Consolidation Durvalumab after Chemoradiation.

Author

Mushonga, Melinda, Louie, Alexander, Cheng, Susanna, Tsao, May N., Ong, Wee Loon, Cheung, Patrick, Poon, Ian, Zhang, L., and Ung, Yee C.

Subjects
RADIATION pneumonitis, PREDICTION models, FISHER exact test, LOGISTIC regression analysis, CHEMORADIOTHERAPY, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, MANN Whitney U Test, MONOCLONAL antibodies, LONGITUDINAL method, LUNG cancer, TUMOR classification, COMPARATIVE studies, PREVENTIVE health services
Abstract

Purpose. Consolidation with durvalumab is standard of care in the management of unresectable stage 3 non-small-cell lung cancer (NSCLC) postchemoradiation, and pneumonitis is an independent potential treatment complication of both treatment strategies. This study seeks to determine the timing of radiation pneumonitis (RP) by receipt of durvalumab. In addition, we reviewed the preventative strategies guided by pathophysiology of pneumonitis. Methods. We identified patients with unresectable Stage 3 NSCLC who developed grade ≥2 RP after chemoradiotherapy. Time-to-RP was defined from date of completion of radiotherapy to date of radiological diagnosis of RP and accompanying clinical symptoms. Early RP was defined as RP within 2 months of completion of radiotherapy. Differences in time-to-RP by receipt of durvalumab were evaluated using Wilcoxon rank-sum test. Differences in those who had early vs late RP by receipt of durvalumab was evaluated using Fisher's exact test. Logistic regression was used to evaluate patient and treatment factors associated with early RP. Results. Of the 144 patients with Stage 3 NSCLC who had definitive chemoradiotherapy, 31 (22%) developed grade ≥2 RP and were included in the study. There was one patient with grade 5 RP. The median age of the cohort was 67 years (range 41–87). The mean lung dose, V5Gy, and V20Gy were 15.8Gy (SD = 1.56), 60.14% (SD 2.73), and 29.96% (SD 1.82), respectively. Twelve (39%) patients received durvalumab. The median time-to-RP was 3.4 months (range: 1.7–7.2) and 2.3 months (range: 0.6–9.6) in patients who had durvalumab and no durvalumab, respectively (P = 0.01). 83% (10/12) of patients who had durvalumab and 58% (11/19) of patients who did not have durvalumab had late RP (P = 0.14). No other patient and treatment factors were associated with early RP. Conclusion. Patients on durvalumab may have late-onset RP; therefore, further studies with larger cohort of patients and development of new predictive models that incorporate evolving management are needed should preventative strategies of RP be considered in routine clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Three Discipline Collaborative Radiation Therapy (3DCRT) special debate: Radiation oncology has become so technologically complex that basic fundamental physics should no longer be included in the modern curriculum for radiation oncology residents

Author

Beriwal, Sushil, primary, Corrigan, Kelsey L., additional, McDermott, Patrick N., additional, Ryckman, Jeffrey, additional, Tsao, May N., additional, Zheng, Dandan, additional, Joiner, Michael C., additional, Dominello, Michael M., additional, and Burmeister, Jay, additional

Published
2023
Full Text
View/download PDF

40. Cancer of the Skin

Author

Lee, Justin, primary, Barnes, Elizabeth, additional, Tsao, May, additional, and Devlin, Phillip, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results